TY - JOUR
T1 - Mutations in the Neuronal Vesicular SNARE VAMP2 Affect Synaptic Membrane Fusion and Impair Human Neurodevelopment
AU - Deciphering Developmental Disorders Study
AU - SYNAPS Study Group
AU - Salpietro, Vincenzo
AU - Malintan, Nancy T.
AU - Llano-Rivas, Isabel
AU - Spaeth, Christine G.
AU - Efthymiou, Stephanie
AU - Striano, Pasquale
AU - Vandrovcova, Jana
AU - Cutrupi, Maria C.
AU - Chimenz, Roberto
AU - David, Emanuele
AU - Di Rosa, Gabriella
AU - Marce-Grau, Anna
AU - Raspall-Chaure, Miquel
AU - Martin-Hernandez, Elena
AU - Zara, Federico
AU - Minetti, Carlo
AU - Kriouile, Yamna
AU - El Khorassani, Mohamed
AU - Aguennouz, Mhammed
AU - Karashova, Blagovesta
AU - Avdjieva, Daniela
AU - Kathom, Hadil
AU - Tincheva, Radka
AU - Van Maldergem, Lionel
AU - Nachbauer, Wolfgang
AU - Boesch, Sylvia
AU - Arning, Larissa
AU - Timmann, Dagmar
AU - Cormand, Bru
AU - Pérez-Dueñas, Belen
AU - Pironti, Erica
AU - Goraya, Jatinder S.
AU - Sultan, Tipu
AU - Kirmani, Salman
AU - Ibrahim, Shahnaz
AU - Jan, Farida
AU - Mine, Jun
AU - Banu, Selina
AU - Veggiotti, Pierangelo
AU - Ferrari, Michel D.
AU - Verrotti, Alberto
AU - Marseglia, Gian Luigi
AU - Savasta, Salvatore
AU - Garavaglia, Barbara
AU - Scuderi, Carmela
AU - Borgione, Eugenia
AU - Dipasquale, Valeria
AU - Cutrupi, Maria Concetta
AU - Portaro, Simona
AU - Sanchez, Benigno Monteagudo
N1 - Funding Information:
We gratefully acknowledge all the families for their enthusiastic participation in this study. This study was supported by the Wellcome Trust (WT093205MA, WT104033AIA); the Medical Research Council (H.H. and D.M.K.); the European Community's Seventh Framework Programme (FP7/2007-2013, under grant agreement No. 2012-305121 to H.H.); the Italian CINECA Awards (HP10CRVL7F, 2017), which made available high-performance computing resources and provided support; the Spanish Instituto de Salud Carlos III (ISCIII) (PI15/01791 A.M.); and the European Regional Development Fund (ERDF) (PI17/00487 to F.M-A.). We are also supported by the National Institute for Health Research (NIHR), the University College London Hospitals (UCLH), and the Biomedical Research Center (BRC).
Publisher Copyright:
© 2019 The Authors
PY - 2019/4/4
Y1 - 2019/4/4
N2 - VAMP2 encodes the vesicular SNARE protein VAMP2 (also called synaptobrevin-2). Together with its partners syntaxin-1A and synaptosomal-associated protein 25 (SNAP25), VAMP2 mediates fusion of synaptic vesicles to release neurotransmitters. VAMP2 is essential for vesicular exocytosis and activity-dependent neurotransmitter release. Here, we report five heterozygous de novo mutations in VAMP2 in unrelated individuals presenting with a neurodevelopmental disorder characterized by axial hypotonia (which had been present since birth), intellectual disability, and autistic features. In total, we identified two single-amino-acid deletions and three non-synonymous variants affecting conserved residues within the C terminus of the VAMP2 SNARE motif. Affected individuals carrying de novo non-synonymous variants involving the C-terminal region presented a more severe phenotype with additional neurological features, including central visual impairment, hyperkinetic movement disorder, and epilepsy or electroencephalography abnormalities. Reconstituted fusion involving a lipid-mixing assay indicated impairment in vesicle fusion as one of the possible associated disease mechanisms. The genetic synaptopathy caused by VAMP2 de novo mutations highlights the key roles of this gene in human brain development and function.
AB - VAMP2 encodes the vesicular SNARE protein VAMP2 (also called synaptobrevin-2). Together with its partners syntaxin-1A and synaptosomal-associated protein 25 (SNAP25), VAMP2 mediates fusion of synaptic vesicles to release neurotransmitters. VAMP2 is essential for vesicular exocytosis and activity-dependent neurotransmitter release. Here, we report five heterozygous de novo mutations in VAMP2 in unrelated individuals presenting with a neurodevelopmental disorder characterized by axial hypotonia (which had been present since birth), intellectual disability, and autistic features. In total, we identified two single-amino-acid deletions and three non-synonymous variants affecting conserved residues within the C terminus of the VAMP2 SNARE motif. Affected individuals carrying de novo non-synonymous variants involving the C-terminal region presented a more severe phenotype with additional neurological features, including central visual impairment, hyperkinetic movement disorder, and epilepsy or electroencephalography abnormalities. Reconstituted fusion involving a lipid-mixing assay indicated impairment in vesicle fusion as one of the possible associated disease mechanisms. The genetic synaptopathy caused by VAMP2 de novo mutations highlights the key roles of this gene in human brain development and function.
KW - SNARE
KW - VAMP2
KW - autism
KW - epilepsy
KW - movement disorders
KW - neurodevelopmental disorders
KW - neuronal exocytosis
KW - synaptobrevin
KW - synaptopathy
KW - vesicle fusion
UR - http://www.scopus.com/inward/record.url?scp=85063684737&partnerID=8YFLogxK
U2 - 10.1016/j.ajhg.2019.02.016
DO - 10.1016/j.ajhg.2019.02.016
M3 - Article
C2 - 30929742
AN - SCOPUS:85063684737
SN - 0002-9297
VL - 104
SP - 721
EP - 730
JO - American Journal of Human Genetics
JF - American Journal of Human Genetics
IS - 4
ER -